Osteoblast Reprogramming via Small Molecule Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing osteoblasts from somatic cells often rely on gene introduction, which carries risks, and there is a lack of techniques for reprogramming somatic cells without gene introduction, particularly for cells that do not inherently have the ability to become osteoblasts.
Innovation Solution
The use of low-molecular-weight compounds such as statin compounds, casein kinase inhibitors, cAMP inducers, and histone methyltransferase inhibitors to directly reprogram differentiated somatic cells into osteoblasts, bypassing the need for gene introduction and pluripotent stem cells, thereby avoiding oncogenesis and immunological rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene introduction methods are used to induce osteoblasts, then osteoblast differentiation can be achieved, but the risk of canceration increases
Solution Approach 1:
The patent extracts and eliminates the harmful gene introduction step from the osteoblast induction process. Instead of using viral vectors or transgenic methods to force osteoblast differentiation, the invention uses small molecule compounds (statins, casein kinase inhibitors, cAMP inducers, histone methyltransferase inhibitors) that naturally trigger the differentiation pathway, thereby removing the canceration risk while maintaining differentiation efficacy
Solution Approach 2:
The patent replaces complex, potentially harmful genetic modification tools with simple, transient small molecule compounds. These compounds act temporarily to induce differentiation without integrating into the genome, effectively using 'disposable' chemical signals rather than permanent genetic changes, thus avoiding oncogenesis
2Quantity of substance
If bone marrow harvesting is performed to obtain osteoblasts, then osteoblasts can be obtained for transplantation, but the procedure becomes very invasive for patients
Solution Approach 1:
The patent changes the source parameter from bone marrow (invasive source) to peripheral blood or other easily accessible tissues (non-invasive sources). By using small molecule compounds to reprogram these easily obtained cells into osteoblasts, the invention maintains adequate osteoblast quantity while dramatically reducing procedural invasiveness
Solution Approach 2:
The patent introduces small molecule compounds as intermediary agents that can convert easily accessible cells (like peripheral blood mononuclear cells) into osteoblasts. These chemical mediators bridge the gap between non-invasive cell collection and osteoblast generation, eliminating the need for invasive bone marrow procedures
3Adaptability or versatility
If existing cell induction methods are used, then cells with inherent differentiation ability can become osteoblasts, but cells that do not have this ability cannot be converted
Solution Approach 1:
The patent inverts the traditional approach by not relying on cells' inherent differentiation ability. Instead of selecting cells that naturally become osteoblasts, the invention uses small molecule compounds to actively reprogram any somatic cell into an osteoblast, effectively working 'the other way round' by imposing differentiation capability rather than selecting for it
Solution Approach 2:
The patent changes the fundamental parameter of cell plasticity by using epigenetic modifiers (histone methyltransferase inhibitors) and signaling pathway modulators to forcibly alter cell fate. This allows cells with completely different inherent properties to be converted into osteoblasts, dramatically increasing adaptability while maintaining reliable differentiation through standardized compound protocols
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
An object of the present invention is to provide a method for preparing osteoblasts that are applicable, without causing risk of canceration, to bone defect repair or to the treatment of bone resorption, fracture, osteoporosis, or the like. To solve this problem, the present invention provides a method for preparing osteoblasts, the method comprising culturing mammal differentiated somatic cells in a medium in the presence of at least one compound selected from the group consisting of (1) statin compounds, (2) casein kinase 1 inhibitors, (3) cAMP inducers, and (4) histone methyltransferase inhibitors, to convert the somatic cells into osteoblasts.